This disclosure is directed to: (a) processes for preparing compounds and salts thereof that, inter alia, are useful for inhibiting hepatitis C virus (HCV) (b) intermediates useful for the preparation of the compounds and salts (c) pharmaceutical compositions comprising the compounds or salts and (d) methods of use of such compositions.